0.8031
price up icon5.67%   0.0431
after-market After Hours: .77 -0.0331 -4.12%
loading
Milestone Pharmaceuticals Inc stock is traded at $0.8031, with a volume of 2.48M. It is up +5.67% in the last 24 hours and down -50.73% over the past month. Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$0.76
Open:
$0.7426
24h Volume:
2.48M
Relative Volume:
1.18
Market Cap:
$40.55M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-0.5778
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
-60.04%
1M Performance:
-50.73%
6M Performance:
-46.46%
1Y Performance:
-55.38%
1-Day Range:
Value
$0.705
$0.8299
1-Week Range:
Value
$0.705
$2.36
52-Week Range:
Value
$0.705
$2.75

Milestone Pharmaceuticals Inc Stock (MIST) Company Profile

Name
Name
Milestone Pharmaceuticals Inc
Name
Phone
(514) 336-0444
Name
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Name
Employee
33
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
MIST's Discussions on Twitter

Compare MIST with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MIST
Milestone Pharmaceuticals Inc
0.8031 40.55M 0 -59.69M -46.54M -1.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-22-24 Initiated Rodman & Renshaw Buy
Jun-20-23 Downgrade Jefferies Buy → Hold
Apr-22-22 Upgrade Piper Sandler Neutral → Overweight
Mar-05-21 Initiated H.C. Wainwright Buy
Jul-29-20 Upgrade Oppenheimer Perform → Outperform
Jul-24-20 Upgrade Jefferies Hold → Buy
Mar-25-20 Downgrade Jefferies Buy → Hold
Mar-24-20 Downgrade Oppenheimer Outperform → Perform
Mar-24-20 Downgrade Piper Sandler Overweight → Neutral
Jun-04-19 Initiated Oppenheimer Outperform
Jun-03-19 Initiated Cowen Outperform
Jun-03-19 Initiated Jefferies Buy
Jun-03-19 Initiated Piper Jaffray Overweight
View All

Milestone Pharmaceuticals Inc Stock (MIST) Latest News

pulisher
03:00 AM

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - TradingView

03:00 AM
pulisher
08:37 AM

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance

08:37 AM
pulisher
02:38 AM

Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World

02:38 AM
pulisher
Apr 01, 2025

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India

Apr 01, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone flagging following CRL - The Pharma Letter

Mar 28, 2025
pulisher
Mar 28, 2025

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma says FDA declined to approve heart disorder therapy - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener

Mar 28, 2025
pulisher
Mar 21, 2025

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

HC Wainwright Brokers Decrease Earnings Estimates for MIST - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Milestone Pharmaceuticals to present clinical data on etripamil - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough PSVT Treatment Data: Etripamil Proves Effective for Multiple Episodes - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Jones Financial Companies Lllp Raises Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

HC Wainwright Has Negative Outlook of MIST FY2028 Earnings - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Milestone Pharmaceuticals sets annual meeting date - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Milestone Pharmaceuticals sets annual meeting date By Investing.com - Investing.com UK

Mar 19, 2025
pulisher
Mar 19, 2025

PDUFA Date Nearing for New PSVT Drug - Streetwise Reports

Mar 19, 2025
pulisher
Mar 19, 2025

Milestone Pharma Expands Sale Agreement, Increases Offering By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 18, 2025

SEC Form 424B5 filed by Milestone Pharmaceuticals Inc. - Quantisnow

Mar 18, 2025
pulisher
Mar 18, 2025

Milestone Pharmaceuticals enters open market sale agreement with Jefferies -March 18, 2025 at 05:51 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Milestone Pharma Expands Sale Agreement, Increases Offering - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Milestone Pharmaceuticals: Buy Rating Backed by Promising FDA Approval and Market Expansion Prospects - TipRanks

Mar 17, 2025
pulisher
Mar 14, 2025

Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 13, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch - TipRanks

Mar 13, 2025

Milestone Pharmaceuticals Inc Stock (MIST) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):